Efficacy of human simulated exposures of ceftaroline administered at 600 milligrams every 12 hours against phenotypically diverse Staphylococcus aureus isolates
about
Ceftaroline fosamil: a brief clinical review.Investigational antimicrobial agents of 2013.Comparison of in vivo and in vitro pharmacodynamics of a humanized regimen of 600 milligrams of Ceftaroline Fosamil every 12 hours against Staphylococcus aureus at initial inocula of 106 and 108 CFU per milliliter.Population Pharmacokinetics of Cefazolin in Serum and Tissue for Patients with Complicated Skin and Soft Tissue Infections (cSSTI).Efficacy of human simulated exposures of ceftaroline against phenotypically diverse Enterobacteriaceae isolatesEfficacy of ceftaroline fosamil in a staphylococcal murine pneumonia model.In vivo efficacy of humanized ceftaroline fosamil-avibactam exposures in a polymicrobial infection modelTissue pharmacokinetics of cefazolin in patients with lower limb infections.Penetration of Ceftaroline into the Epithelial Lining Fluid of Healthy Adult Subjects.Efficacy of humanized carbapenem and ceftazidime regimens against Enterobacteriaceae producing OXA-48 carbapenemase in a murine infection model.In vivo efficacy of human simulated regimens of carbapenems and comparator agents against NDM-1-producing Enterobacteriaceae.Ceftaroline fosamil for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection.Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia.Ceftaroline fosamil for the treatment of acute bacterial skin and skin structure infections.Pharmacokinetic and pharmacodynamic evaluation of ceftaroline fosamil.Efficacy of Ceftaroline against Methicillin-Susceptible Staphylococcus aureus Exhibiting the Cefazolin High-Inoculum Effect in a Rat Model of Endocarditis.Ceftaroline Fosamil: A Review in Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia.In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposurePharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection.Ceftaroline efficacy against high-MIC clinical Staphylococcus aureus isolates in an in vitro hollow-fibre infection model.Development and Validation of Stability Indicating RP-HPLC Method for Estimation of Ceftaroline Fosamil in Bulk and Its Parenteral Dosage Forms
P2860
Q33939080-CE8F1E4F-F27B-4786-A281-BED8018B75B9Q34375204-B1F766F4-2363-4BF4-B48C-DA97B4996816Q34596470-267899CF-A373-4EBF-BA3C-5ABF2A34490DQ34726196-0CFC6DD2-FD32-445B-B796-6D41472E013FQ35941308-C21BD2C1-1DC3-4C82-BE9E-8F4CFA5B9634Q36396172-10B9F5A7-D71E-4989-B92D-3014A12D5800Q37263439-1AF75936-2B82-4670-A3CC-60C0BF4D766FQ37263523-782F2A7F-62EA-4692-B19D-164FB617A98EQ37287884-99C6E47C-EA16-41AD-9B71-D0B67DFD49EFQ37643634-3DCB5C5B-4825-43E1-A5D4-92C134A77E8EQ37643705-A5C83761-2864-4C2F-8615-F2ED6F9DE775Q38010783-9E4C329B-A941-4554-AEBE-EEF2EBB06AFDQ38025132-FEB15CA8-FFF2-4B65-821D-9CD198B6B03FQ38117077-187B33BF-668C-480F-971A-712C67832352Q38185097-9B7FD9F9-BB73-48FD-8D86-92158FE31C31Q38262950-C6F277B9-7D78-4A06-954B-92267B9D20ADQ38797012-C2891C23-60B3-4792-81F4-87B260CB9397Q38987098-15946F92-88A6-4B5F-9EBB-52D103029027Q41825567-B224B08C-ED63-48B5-8E3F-C69FA19D51CAQ42275442-6B7C943C-86CB-4640-A70E-69ACEC8E3E53Q47677671-3FAEC95A-3E2E-497B-B126-12D2A835F9E7Q58995336-E2BD975D-F9B5-48B9-A9CF-CE57BD1A9B1C
P2860
Efficacy of human simulated exposures of ceftaroline administered at 600 milligrams every 12 hours against phenotypically diverse Staphylococcus aureus isolates
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Efficacy of human simulated ex ...... Staphylococcus aureus isolates
@ast
Efficacy of human simulated ex ...... Staphylococcus aureus isolates
@en
type
label
Efficacy of human simulated ex ...... Staphylococcus aureus isolates
@ast
Efficacy of human simulated ex ...... Staphylococcus aureus isolates
@en
prefLabel
Efficacy of human simulated ex ...... Staphylococcus aureus isolates
@ast
Efficacy of human simulated ex ...... Staphylococcus aureus isolates
@en
P2093
P2860
P356
P1476
Efficacy of human simulated ex ...... Staphylococcus aureus isolates
@en
P2093
David P Nicolau
Jared L Crandon
Rebecca A Keel
P2860
P304
P356
10.1128/AAC.00372-11
P407
P577
2011-06-13T00:00:00Z